Lexaria Bioscience (LEXX) has begun dosing in the Company’s Phase 1b, 12-week chronic study GLP-1-H24-4. The Study is designed mainly to determine whether Lexaria’s proprietary DehydraTECH technology ...
(RTTNews) - Friday, Precision BioSciences, Inc. (DTIL) announced a 1-for-30 reverse stock split of its common stock, effective February 13, 2024, after the close of trading on The Nasdaq Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results